Clinical Application of AMH Measurement in Assisted Reproduction

• Published in: Frontiers in endocrinology (Lausanne) Vol. 11; p. 606744
• Main Authors: Li, Hang Wun Raymond, Nelson, Scott M
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 09.12.2020
• Subjects: anti-Müllerian hormone; assisted reproduction; Endocrinology; gonadotropin dosing; in vitro fertilization; intrauterine insemination; ovarian response; in vitro fertilization; assisted reproduction; anti-Müllerian hormone; intrauterine insemination; gonadotropin dosing; ovarian response
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2020.606744

Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients.